ADAMTS13-containing compositions having thrombolytic activity
This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof. Furthermore, the invention relates to the use of a pharmaceutically effective amount of ADAMTS13 for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation or the presence of one or more thrombus and for disintegrating one or more thrombus in a patient in need thereof.
1 . A pharmaceutical composition having thrombolytic activity, comprising a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof.
2 . The pharmaceutical composition according to claim 1 , wherein ADAMTS13 is recombinant human ADAMTS13 or a biologically active derivative thereof.
3 . The pharmaceutical composition according to claim 1 , wherein the biologically active derivative is a chimeric molecule comprising ADAMTS13 or a biologically active derivative thereof and Ig or a biologically active derivative thereof.
4 . The pharmaceutical composition according to claim 1 , further comprising one or more additional active ingredient.
5 . The pharmaceutical composition according to claim 4 , wherein the additional active ingredient is selected from the group consisting of antithrombic agents; agents that stimulate ADAMTS13 production/secretion; agents that inhibit ADAMTS13 degradation; agents that enhance ADAMTS13 activity; and agents that inhibit ADAMTS13 clearance from circulation.
6 . The pharmaceutical composition according to claim 5 , wherein the anti-thrombotic agent is selected from the group consisting of anti-platelets, t-PA, aspirin and heparin.
7 . A method of treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus, comprising the step of administering a composition according to claim 1 to a patient.
8 . A method according to claim 7 , wherein the disorder is selected from the group consisting of hereditary thrombotic thrombocytopenic purpura (TTP), acquired TTP, arterial thrombosis, acute myocardial infarction (AMI), stroke, sepsis, disseminated intravascular coagulation (DIC), and venous thrombosis, such as e.g. deep vein thrombosis or pulmonary embolism.
9 . A method of disintegrating one or more thrombus in a patient in need thereof, comprising the step of administering a composition according to claim 1 to said patient.
10 . The use of a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof for the preparation of a pharmaceutical composition for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus.
11 . The use according to claim 10 , wherein the disorder is selected from the group consisting of hereditary thrombotic thrombocytopenic purpura (TTP), acquired TTP, arterial thrombosis, acute myocardial infarction (AMI), stroke, sepsis, disseminated intravascular coagulation (DIC), and venous thrombosis, such as e.g. deep vein thrombosis or pulmonary embolism.
12 . The use of a pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof for the preparation of pharmaceutical composition for disintegrating one or more thrombus in a patient in need thereof.
13 . The use according to one of claims 10 or 12 , wherein the pharmaceutically effective amount of ADAMTS13 or a biologically active derivative thereof ranges from 0.1 to 20 mg/kg body weight.